Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyGlobeNewsWire • Wednesday
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyPRNewsWire • Wednesday
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalGlobeNewsWire • 04/04/24
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationGlobeNewsWire • 04/03/24
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/13/24
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)GlobeNewsWire • 03/11/24
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyGlobeNewsWire • 02/23/24
CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyPRNewsWire • 02/23/24
Travere (TVTX) Q4 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 02/15/24
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/15/24
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 02/08/24
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology ConferenceGlobeNewsWire • 02/01/24
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian NationsGlobeNewsWire • 01/25/24
Wall Street Analysts Think Travere (TVTX) Could Surge 66.29%: Read This Before Placing a BetZacks Investment Research • 01/17/24
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/02/24
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)GlobeNewsWire • 12/14/23
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceGlobeNewsWire • 11/21/23
Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 11/08/23